CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.
ARK also continued its buying trend in CRISPR Therapeutics AG (NASDAQ:CRSP), acquiring 39,250 shares valued at $2,142,265. This purchase adds to the fund’s recent accumulation of CRISPR stock over the ...
CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...
Investor's Business Daily on MSN
Why Gene-Editing Giants Crispr And Intellia Just Surged
Crispr stock jumped Monday while Intellia shares surged on promising updates for their gene-editing efforts in cholesterol ...
Investing.com -- Intellia Therapeutics Inc (NASDAQ:NTLA) stock soared 13.8% in premarket trading Monday after the gene editing company presented positive clinical data for its hereditary angioedema ...
Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback